SIGN IN
This site is for Healthcare Professionals only | Consumer Site
Visit ZyrtecProfessional.com for additional allergy management information and products.

RHINOCORT® Allergy Spray is generally well tolerated

  • Generally well tolerated in adults and children 6 years of age and older1

Adverse reactions in clinical trials occurring at an incidence of 2% and more commonly than placebo in the RHINOCORT® group in patients 6 years and older*

RHINOCORT® vs. placebo Comparison Chart RHINOCORT® vs. placebo Comparison Chart

A similar adverse event profile was observed in the subgroup of pediatric patients 6-12 years of age. These patients are included in the table. Two to three percent (2%-3%) of patients in the clinical trials discontinued because of adverse reactions.

* Based on 7 controlled clinical studies (N=1526) in adults and children ≥ 6 years old with SAR or PAR treated with RHINOCORT® Allergy Spray at doses up to 400 mcg once daily for 3-6 weeks.

Discontinuation rate

2%-3% of patients in clinical trials discontinued due to adverse reactions

Reference:

  1. Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 1998;81(2):128-134.

See data for use in specific populations: pregnancy

Must be signed in to view.